Israel Englander’s Tyra Biosciences TYRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.67M Sell
177,672
-43,909
-20% -$1.45M ﹤0.01% 2873
2026
Q1
$8.49M Buy
221,581
+107,193
+94% +$3.47M ﹤0.01% 2335
2025
Q4
$3.01M Sell
114,388
-29,628
-21% -$544K ﹤0.01% 3554
2025
Q3
$2.01M Sell
144,016
-263,448
-65% -$3M ﹤0.01% 4057
2025
Q2
$3.9M Buy
407,464
+3,299
+0.8% +$31.3K ﹤0.01% 3242
2025
Q1
$3.76M Buy
404,165
+89,024
+28% +$1.15M ﹤0.01% 3145
2024
Q4
$4.38M Buy
315,141
+304,637
+2,900% +$5.53M ﹤0.01% 2935
2024
Q3
$247K Buy
+10,504
New +$221K ﹤0.01% 5315
2023
Q3
Sell
-21,591
Closed -$368K 6584
2023
Q2
$368K Buy
21,591
+8,116
+60% +$118K ﹤0.01% 4759
2023
Q1
$217K Buy
+13,475
New +$160K ﹤0.01% 5127
2022
Q1
Sell
-109,523
Closed -$1.54M 7505
2021
Q4
$1.54M Buy
109,523
+16,022
+17% +$318K ﹤0.01% 4007
2021
Q3
$1.65M Buy
+93,501
New +$1.79M ﹤0.01% 4140

Other funds holding TYRA

Israel Englander's TYRA Position: Q2 2026 in Review

Israel Englander reduced its Tyra Biosciences (TYRA) stake by 20% in Q2 2026, selling an estimated $1.45M and leaving 177,672 shares worth $5.67M. The position accounts for ﹤0.01% of the portfolio, ranked #2873.

Israel Englander first reported a position in TYRA in Q3 2021 and has held it in 12 quarters since. The position peaked at $8.49M in Q1 2026. 169 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

  • Israel Englander held 177,672 shares of Tyra Biosciences worth $5.67M as of Q2 2026.
  • Israel Englander sold 43,909 Tyra Biosciences shares in Q2 2026, an estimated $1.45M.
  • Tyra Biosciences made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2873 holding.
  • Israel Englander first reported a position in Tyra Biosciences in Q3 2021 and has held it in 12 quarters since.
  • Israel Englander's Tyra Biosciences position peaked at $8.49M in Q1 2026.
  • 169 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.